Search

Your search keyword '"Moiola, L."' showing total 625 results

Search Constraints

Start Over You searched for: Author "Moiola, L." Remove constraint Author: "Moiola, L."
625 results on '"Moiola, L."'

Search Results

1. Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors

4. Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study

7. Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study

8. Signs and symptoms of COVID-19 in patients with multiple sclerosis

11. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement

12. Vaccinations in patients with multiple sclerosis: A Delphi consensus statement

16. Signs and symptoms of COVID-19 in patients with multiple sclerosis

17. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

19. Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases

22. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs

27. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility

28. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France: a pooled analysis from Italy and France

29. Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis

31. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

34. Results from an Italian consensus conference on prevention and management of infections in MS patients treated with biological and non biological disease modifying drugs

37. Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain: Abstracts of Symposia and free communications

38. This title is unavailable for guests, please login to see more information.

39. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases

41. The still under-investigated role of cognitive deficits in PML diagnosis

42. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

44. Early diagnosis of progressive multifocal leucoencephalopathy: Longitudinal lesion evolution

45. NEDA 3 in multiple sclerosis preserves from retinal axonal loss

46. Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group

48. Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases

50. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

Catalog

Books, media, physical & digital resources